Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Glycorex Transplantation AB operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Glycorex Transplantation AB's Operating Margin % or its related term are showing as below:
NGM:GTAB B'
s Operating Margin % Range Over the Past 10 Years
Min: -101.26 Med: -26 Max: 20.62
Current: -24.41
NGM:GTAB B's Operating Margin % is ranked better than 61.61% of 943
companies
in the Biotechnology industry
Industry Median: -86.94
vs NGM:GTAB B: -24.41
Glycorex Transplantation AB (NGM:GTAB B) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Glycorex Transplantation AB Operating Margin % Related Terms
Glycorex Transplantation AB Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB Operating Margin % Chart
NGM:GTAB B vs VRTX, REGN, RVMD: Operating Margin % Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's Operating Margin % falls into.
Glycorex Transplantation AB Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Glycorex Transplantation AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB (NGM:GTAB B) has a Operating Margin % of -39.09% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Glycorex Transplantation AB and its competitors. According to the industry distribution chart, Glycorex Transplantation AB ranks #362 out of 943 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Glycorex Transplantation AB's Operating Margin % too high?
Glycorex Transplantation AB's current Operating Margin % is -39.09%. Based on the distribution chart, Glycorex Transplantation AB ranks #362 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #362 out of 943 companies for Operating Margin %. This puts Glycorex Transplantation AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current Operating Margin % is -39.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (NGM:GTAB B) is currently considered Modestly Undervalued. The stock's GF Value™ is kr1.81, compared to a current price of kr1.46 — trading 19.3% below its estimated fair value. The current Operating Margin % is -39.09%. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Glycorex Transplantation AB (NGM:GTAB B), the current Operating Margin % is -39.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (NGM:GTAB B) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of kr1.46 is trading 19.3% below its estimated GF Value™ of kr1.81.
GuruFocus considers Glycorex Transplantation AB to be Modestly Undervalued.
Key valuation signals for NGM:GTAB B:
Operating Margin %: -39.09%
GF Value™: kr1.81 vs. price of kr1.46 (19.3% below fair value)
No single metric tells the full story. See the NGM:GTAB B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for NGM:GTAB B
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:GTAB B has been successfully added to your 
